Borderline Personality Disorder (BPD)

This report summarises what Blossom’s database shows about psychedelics and borderline personality disorder, and the headline is unusual: this is a field defined more by who has been left out of it than by what has been found. People with BPD have largely been excluded from psychedelic trials, so the direct evidence is tiny, and the little that exists, a negative ketamine trial and a nine-person psilocybin study, does not yet support the hopeful narrative the mechanism invites.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. BPD is associated with high rates of self-harm and suicide, and the treatments discussed here are experimental, largely untested in BPD, and carry a real risk of emotional destabilisation. Crucially, BPD has treatments that genuinely work: structured psychotherapies such as dialectical behaviour therapy reduce self-harm and suicidality, and they, not psychedelics, are the evidence-based foundation of care. If you live with BPD and are struggling, please stay connected to your mental-health team or a crisis service; this is not a condition to self-treat with these substances.

A word on scope and numbers. Blossom tracks only a handful of papers and trials under this topic, and most of them are reviews, mechanistic studies, or work on conditions that merely co-occur with BPD. The number of completed clinical studies in diagnosed BPD is very small, effectively one randomised trial and one tiny open-label study. Read the counts as a field at its very beginning, not as a body of evidence.

A research gap that is partly deliberate

The first thing to understand is why there is so little to report. Psychedelic trials routinely screen out people at high risk of suicide, those with significant emotional instability, and those prone to dissociation, because of the genuine risks of a powerful, mind-altering experience in such individuals. Those exclusion criteria describe BPD almost exactly. So people with the disorder have been systematically kept out of the research, and the resulting evidence gap is not simple neglect; it reflects a real and reasonable caution about safety.

That caution is not just bureaucratic. The core of a psychedelic experience, intense emotion, altered sense of self, sometimes dissociation or a frightening loss of control, maps onto the very vulnerabilities that define BPD: emotional dysregulation, an unstable identity, and a tendency to dissociate under stress. The worry that such an experience could destabilise rather than heal is specific and plausible, and it has to be held alongside any optimism about benefit. This is the unusual situation of BPD: the same features that make the rationale appealing also make the risk real.

Why the rationale is nonetheless serious

Against that caution sits a genuinely strong theoretical case, which is why the field exists at all. BPD overlaps heavily with complex trauma, and at its heart it is a disorder of emotion regulation and insecure attachment. Those are precisely the targets of emotion-focused psychedelic therapies. A 2022 review of MDMA-assisted psychotherapy for BPD[1]Focus (APA), MDMA-assisted psychotherapy for BPD review (2022) makes the argument in full: MDMA reduces fear and defensiveness and increases trust and emotional openness, which could allow the kind of difficult therapeutic processing that BPD treatment requires. There is even a mechanistic hint from a different compound, a study finding that ayahuasca improved emotion dysregulation in people with borderline-like traits[2]Psychopharmacology, ayahuasca and emotion dysregulation in borderline-like traits (2018), which speaks directly to BPD’s central problem.

So the rationale is not hand-waving. If you set out to design a condition that emotion-focused psychedelic therapy might suit, you might well describe something like BPD. The question the field now faces is whether that elegant theory survives contact with a population in which the same treatment could just as easily do harm, and whether it can be delivered safely enough to find out.

What the direct evidence actually shows

Here the story turns sober. The only randomised controlled trial conducted specifically in BPD tested ketamine, and it was negative. Twenty-two participants received either ketamine or an active placebo, and ketamine showed no significant benefit for suicidal ideation, depression, anxiety or BPD symptom severity[3]Neuropsychopharmacology, pilot RCT of ketamine in BPD (2023), though it was safe and well tolerated. Because ketamine is so often hoped to help suicidality quickly, a null result in exactly the population where that hope is greatest is an important corrective.

The only direct psilocybin data come from a small open-label study in nine people with BPD and co-occurring major depression[4]Clin Neuropharmacol, open-label psilocybin for BPD with co-occurring MDD (2026), which targeted the depression and can show feasibility but not efficacy. And the more encouraging ketamine numbers come from uncontrolled, real-world studies in treatment-resistant depression where some participants also had BPD[5]Psychiatry Research, ketamine for TRD with comorbid BPD real-world (2023), which are treating depression, not BPD, and cannot be read as evidence for the disorder. There is also a deflating signal from the wider literature: personality-disorder features have been associated with weaker responses to psilocybin for depression, hinting that BPD traits might dampen rather than enhance the effect. Put together, the direct evidence is not just thin, it is, so far, unpromising.

Reading this honestly

So where does BPD sit? It is the clearest example in this whole field of a gap between theory and evidence. The theory is genuinely attractive: a disorder of trauma, emotion and attachment, met by therapies built to work on exactly those things. The evidence is almost empty, and what little exists, a negative ketamine trial, a nine-person psilocybin study, a hint that BPD traits blunt the response, points the other way. Layered on top are a real risk of destabilising vulnerable, suicide-prone people, a history of justified exclusion from trials, and, crucially, a psychotherapy that already works. For people living with BPD, the truthful message is that this is an area of serious, careful research and real hope on paper, but not yet a treatment, not a substitute for dialectical behaviour therapy and the other proven approaches, and not something to pursue outside a trial. The most valuable thing the field can now do is study this population directly, safely, and without overselling what it finds.